招银国际每日投资策略-20260112

Group 1: Market Overview - The Hang Seng Index closed at 26,232, up 0.32% for the day and 2.35% year-to-date [1] - The Shanghai Composite Index rose by 0.92% to 4,120, with a year-to-date increase of 3.82% [1] - The US markets showed positive performance, with the Dow Jones up 0.48% and the S&P 500 up 0.65% [1] Group 2: Sector Performance - In the Hong Kong market, the financial sector increased by 0.20%, while the real estate sector rose by 0.32% [2] - Chinese stocks saw gains in materials, consumer discretionary, and integrated enterprises, while consumer staples and utilities declined [3] - The MSCI China Healthcare Index has risen by 11.8% since the beginning of 2026, outperforming the MSCI China Index which increased by 9.1% [5] Group 3: Economic Indicators - China's CPI growth has slightly increased, reaching a near two-year high, driven by rising food and gold jewelry prices [4] - The US non-farm payrolls for December fell short of expectations, indicating a weakening job market, with the unemployment rate dropping to 4.4% [4] - The basic medical insurance expenditure in China showed a recovery with a 0.5% growth in 2025, compared to a 5.5% increase in 2024 [9] Group 4: Pharmaceutical Industry Insights - The market size for patented drugs in China is estimated to be around 300-400 billion RMB, with domestic innovative drugs accounting for about 1/3 of this market [6] - The global pharmaceutical market is projected to reach 1.74 trillion USD, with China's market size at 166 billion USD, representing only 9.5% of the global market [7] - The trend of Chinese innovative drugs going overseas is expected to continue, with a significant increase in BD (business development) transactions projected for 2025 [8]